Catalyst Wire Dossier Catalyst Wire Dossier

SVN53-67/M57-KLH peptide vaccine

SVN53-67/M57-KLH peptide vaccine · Roswell Park Cancer Institute
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SVN53-67/M57-KLH peptide vaccine, covering 2025-05-11 to 2025-05-11. Get the full timeline:

Most recent: Clinical Trial Update: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy [Phase 1]

See pricing